Rosacea
Supporting the internal factors associated with rosacea — inflammatory signalling, skin barrier and vascular function, and the gut-skin axis.
The biological basis of rosacea — and how internal support fits alongside treatment.
Rosacea is influenced by both surface events and internal biological function. While topical and prescription treatments act primarily at the skin’s surface, the features that characterise rosacea are governed by underlying biology — a heightened inflammatory and immune response, altered neurovascular signalling that affects facial blood vessels, and a compromised skin barrier.
Dermatology literature describes rosacea as a chronic inflammatory condition in which these processes interact, with flushing, redness and sensitivity reflecting both vascular and inflammatory activity. Internal factors are increasingly discussed as part of the picture — inflammatory and oxidative balance, micronutrient status, and the gut-skin axis — together shaping the internal environment in which the skin manages inflammation and maintains its barrier.
The Rosacea formulation is designed to support the internal cofactors these processes depend on — providing a consistent internal foundation that sits alongside a patient’s topical or prescribed treatment, not in place of it.
What’s in the Rosacea formulation — and why
This formulation represents the standard base composition for rosacea-prone skin, designed for general clinical use and practitioner-led recommendation.
Each active is included at a defined dose for its documented role in a pathway relevant to rosacea. Calibrated to levels supported by published evidence — a key advantage of pharmacist compounding over standardised manufactured supplements.
| Ingredient | Primary pathway relevance | Mechanism | Evidence summary | Key reference |
|---|---|---|---|---|
| Polydatin50 mg | Inflammatory signalling; skin defence | Modulates keratinocyte inflammatory signalling and antimicrobial peptide production | Laboratory studies in human keratinocytes demonstrate modulation of inflammatory pathways and increased β-defensin production | Ravagnan G et al. Inflammation. 2013;36(1):26–34 |
| Palmitoylethanolamide (PEA)300 mg | Neuro-inflammatory; mast-cell pathways | Endogenous lipid mediator modulating mast-cell and inflammatory signalling | Human studies support PEA in inflammatory and sensory signalling — pathways relevant to the flushing and sensitivity associated with rosacea | Petrosino S, Di Marzo V. British Journal of Pharmacology. 2017;174(11):1349–1365 |
| Selenomethionine50 mcg (selenium 20 mcg) | Antioxidant defence | Cofactor for glutathione peroxidase and antioxidant enzymes | Cofactor for glutathione peroxidase, supporting the antioxidant enzyme systems that regulate oxidative balance in inflamed skin | Lv J et al. Journal of Trace Elements in Medicine and Biology. 2020;62:126548 |
| Vitamin B5 (pantothenic acid)10 mg | Skin lipid metabolism | Precursor to coenzyme A supporting fatty-acid metabolism | Included as a nutritional cofactor for normal skin lipid metabolism | NIH Office of Dietary Supplements. Pantothenic Acid Fact Sheet. |
| Zinc picolinate50 mg (elemental zinc ~10 mg) | Immune & inflammatory regulation | Contributes to immune regulation and inflammatory control | Zinc contributes to immune regulation and inflammatory control, and has been evaluated in randomised rosacea trials | Sharquie KE et al. International Journal of Dermatology. 2006;45(7):857–861; Bamford JT et al. 2012;51(4):459–462 |
| Vitamin A1000 IU | Epithelial differentiation | Supports normal epithelial differentiation and function | Supports normal epithelial differentiation and function. Provided at a nutritional dose — not equivalent to prescription retinoids | Algarin YA et al. Archives of Dermatological Research. 2024;316(5):142 |
| Vitamin D3 (cholecalciferol)1000 IU | Immune regulation | Participates in innate and adaptive immune signalling | Participates in innate and adaptive immune signalling, relevant to the inflammatory features of rosacea | Algarin YA et al. Archives of Dermatological Research. 2024;316(5):142 |
References describe the pathway and supporting evidence relevant to each ingredient. This formulation supports the biological processes associated with rosacea and is not intended to diagnose, treat, cure or prevent the condition.
Pharmaceutical-grade precision. Every ingredient has a purpose.
The Rosacea formulation is compounded by licensed Australian pharmacists within established TGA regulatory frameworks, using pharmaceutical-grade raw materials selected for documented roles in inflammatory regulation, antioxidant defence and barrier support.
The compounding approachTwo contexts, one formulation
The Rosacea formulation is designed to support skin from within as part of a patient’s daily routine. For patients managing persistent redness and flares, it provides a consistent internal foundation targeting inflammatory and antioxidant balance and the factors associated with barrier and vascular function.
Topical and prescription rosacea therapies act on the skin’s surface and local vascular and inflammatory processes. This formulation supports the internal resources — inflammatory balance, micronutrient status and gut-skin factors — that sit beneath those surface processes, complementing existing treatment rather than replacing it.
Ready to order the Rosacea formulation for your clinic?
All formulations are compounded fresh to order and shipped directly to your clinic.